FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000821511> ?p ?o ?g. }

• W2000821511 endingPage "15" @default.
• W2000821511 startingPage "3" @default.
• W2000821511 abstract "Objective: Intratympanic steroids are increasingly used in the treatment of inner ear disorders, especially in patients with sudden sensorineural hearing loss (SNHL) who have failed systemic therapy. We reviewed our experience with intratympanic steroids in the treatment of patients with sudden SNHL to determine overall success, morbidity, and prognostic factors. Hypothesis: Intratympanic steroids have minimal morbidity and the potential to have a positive effect on hearing recovery in patients with sudden SNHL who have failed systemic therapy. Study Design: The authors conducted a retrospective review. Methods: Patients presenting with sudden SNHL defined as a rapid decline in hearing over 3 days or less affecting 3 or more frequencies by 30 dB or greater who underwent intratympanic steroids therapy (24 mg/mL dexamethasone) were reviewed. Excluded were patients with Meniere disease, retrocochlear disease, autoimmune HL, trauma, fluctuating HL, radiation-induced HL, noise-induced HL, or any other identifiable etiology for sudden HL. Patients who showed signs of fluctuation of hearing after injection were excluded. Pretreatment and posttreatment audiometric evaluations including pure-tone average (PTA) and speech reception threshold (SRT) were analyzed. Patient variables as they related to recovery were studied and included patient age, time to onset of therapy, status of the contralateral ear, presence of diabetes, severity of HL, and presence of associated symptoms (tinnitus, vertigo). A 20-dB gain in PTA or a 20% improvement in SDS was considered significant. Results: Forty patients fit the criteria for inclusion in the study. The mean age of the patients was 54.8 years with a range from 17 to 84 years of age. Overall, 40% (n = 16) showed any improvement in PTA or SDS. Fourteen (35%) men and 26 (65%) women were included. Using the criteria of 20-dB improvement in PTA or 20% improvement in SDS for success, 27.5% (n = 11) showed improvement. The mean number of days from onset of symptoms to intratympanic therapy was 40 days with a range of 7 days to 310 days. A statistically significant difference was noted in those patients who received earlier injection (P = .0008, rank sum test). No patient receiving intratympanic dexamethasone after 36 days recovered hearing using 20-dB PTA decrease or a 20% increase in discrimination as criteria for recovery. Twelve percent (n = 5) of patients in the study had diabetes with 20% recovering after intratympanic dexamethasone (not significantly different from nondiabetics at 28.6%, Fisher exact test, P = 1.0). Comparison to other studies that used differing steroid type, concentration, dosing schedule, inclusion criteria, and criteria for success revealed, in many instances, a similar overall recovery rate. Conclusions: Difficulty in proving efficacy of a single modality is present in all studies on SNHL secondary to multiple treatment protocols, variable rates of recovery, and a high rate of spontaneous recovery. Forty percent of patients showed some improvement in SDS or PTA after treatment failure. When criteria of 20-dB PTA or 20% is considered to define improvement, the recovery rate was 27.5%. Modest improvement is seen with the current protocol of a single intratympanic steroid injection of 24 mg/mL dexamethasone in patients who failed systemic therapy. Dramatic hearing recovery in treatment failures was rarely encountered. No patient showed significant benefit from intratympanic steroids after 36 days when using this protocol for idiopathic sudden SNHL. If patients injected after 6 weeks are excluded from the study, the improvement rate increases from 26.9% to 39.3%. Earlier intratympanic injection had a significant impact on hearing recovery, although with any therapeutic intervention for sudden SNHL, early success may be attributed to natural history. If we further exclude seven patients treated with intratympanic steroids within 2 weeks of the onset of symptoms (i.e., study only those patients treated with intratympanic dexamethasone between 2 and 6 weeks after onset of symptoms), still, 26% improved by 20 dB or 20% SDS. The recovery rates after initial systemic failure are higher than would be expected in this treatment failure group given our control group (9.1%) and literature review. These findings indicate a positive effect from steroid perfusion in this patient population." @default.
• W2000821511 created "2016-06-24" @default.
• W2000821511 creator A5002501678 @default.
• W2000821511 creator A5055979252 @default.
• W2000821511 creator A5056906575 @default.
• W2000821511 creator A5080722345 @default.
• W2000821511 creator A5091644232 @default.
• W2000821511 date "2007-01-01" @default.
• W2000821511 modified "2023-09-25" @default.
• W2000821511 title "Intratympanic Dexamethasone for Sudden Sensorineural Hearing Loss After Failure of Systemic Therapy" @default.
• W2000821511 cites W1971528716 @default.
• W2000821511 cites W1972706118 @default.
• W2000821511 cites W1981044848 @default.
• W2000821511 cites W1983240266 @default.
• W2000821511 cites W1988195001 @default.
• W2000821511 cites W1989008304 @default.
• W2000821511 cites W1989761558 @default.
• W2000821511 cites W1991300638 @default.
• W2000821511 cites W2001165455 @default.
• W2000821511 cites W2007346737 @default.
• W2000821511 cites W2011724372 @default.
• W2000821511 cites W2031740656 @default.
• W2000821511 cites W2034812638 @default.
• W2000821511 cites W2035428180 @default.
• W2000821511 cites W2035471615 @default.
• W2000821511 cites W2035592425 @default.
• W2000821511 cites W2036110399 @default.
• W2000821511 cites W2036197069 @default.
• W2000821511 cites W2037017062 @default.
• W2000821511 cites W2038976850 @default.
• W2000821511 cites W2045891434 @default.
• W2000821511 cites W2047464159 @default.
• W2000821511 cites W2050445688 @default.
• W2000821511 cites W2051128881 @default.
• W2000821511 cites W2053488801 @default.
• W2000821511 cites W2059761123 @default.
• W2000821511 cites W2065270655 @default.
• W2000821511 cites W2065903443 @default.
• W2000821511 cites W2068187142 @default.
• W2000821511 cites W2068767177 @default.
• W2000821511 cites W2070447196 @default.
• W2000821511 cites W2072293525 @default.
• W2000821511 cites W2072681852 @default.
• W2000821511 cites W2074233512 @default.
• W2000821511 cites W2074677746 @default.
• W2000821511 cites W2076408736 @default.
• W2000821511 cites W2081453354 @default.
• W2000821511 cites W2089874274 @default.
• W2000821511 cites W2092953133 @default.
• W2000821511 cites W2100882276 @default.
• W2000821511 cites W2115275344 @default.
• W2000821511 cites W2134341902 @default.
• W2000821511 cites W2135336918 @default.
• W2000821511 cites W2137588072 @default.
• W2000821511 cites W2152587898 @default.
• W2000821511 cites W3132420242 @default.
• W2000821511 cites W3022282944 @default.
• W2000821511 doi "https://doi.org/10.1097/01.mlg.0000245058.11866.15" @default.
• W2000821511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17202923" @default.
• W2000821511 hasPublicationYear "2007" @default.
• W2000821511 type Work @default.
• W2000821511 sameAs 2000821511 @default.
• W2000821511 citedByCount "248" @default.
• W2000821511 countsByYear W20008215112012 @default.
• W2000821511 countsByYear W20008215112013 @default.
• W2000821511 countsByYear W20008215112014 @default.
• W2000821511 countsByYear W20008215112015 @default.
• W2000821511 countsByYear W20008215112016 @default.
• W2000821511 countsByYear W20008215112017 @default.
• W2000821511 countsByYear W20008215112018 @default.
• W2000821511 countsByYear W20008215112019 @default.
• W2000821511 countsByYear W20008215112020 @default.
• W2000821511 countsByYear W20008215112021 @default.
• W2000821511 countsByYear W20008215112022 @default.
• W2000821511 countsByYear W20008215112023 @default.
• W2000821511 crossrefType "journal-article" @default.
• W2000821511 hasAuthorship W2000821511A5002501678 @default.
• W2000821511 hasAuthorship W2000821511A5055979252 @default.
• W2000821511 hasAuthorship W2000821511A5056906575 @default.
• W2000821511 hasAuthorship W2000821511A5080722345 @default.
• W2000821511 hasAuthorship W2000821511A5091644232 @default.
• W2000821511 hasConcept C126322002 @default.
• W2000821511 hasConcept C137627325 @default.
• W2000821511 hasConcept C141071460 @default.
• W2000821511 hasConcept C167135981 @default.
• W2000821511 hasConcept C2776992516 @default.
• W2000821511 hasConcept C2779135839 @default.
• W2000821511 hasConcept C2780401358 @default.
• W2000821511 hasConcept C2780493683 @default.
• W2000821511 hasConcept C2780554537 @default.
• W2000821511 hasConcept C548259974 @default.
• W2000821511 hasConcept C71924100 @default.
• W2000821511 hasConceptScore W2000821511C126322002 @default.
• W2000821511 hasConceptScore W2000821511C137627325 @default.
• W2000821511 hasConceptScore W2000821511C141071460 @default.
• W2000821511 hasConceptScore W2000821511C167135981 @default.
• W2000821511 hasConceptScore W2000821511C2776992516 @default.
• W2000821511 hasConceptScore W2000821511C2779135839 @default.

• next